Autopsy report · NCT00623077

MT2004-30: Tomotherapy for Solid Tumors

“Replaced by another study”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 years 6 months after it had already started.
• Ran for about 11 years 2 months before it stopped.
• 23 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Masonic Cancer Center, University of Minnesota

Sponsor type

University, hospital or other

Conditions

Brain and Central Nervous System Tumors; Kidney Cancer; Liver Cancer; Retinoblastoma; Sarcoma

Interventions

filgrastim; busulfan; etoposide; ifosfamide; melphalan; thiotepa

Participants

23

Sites

1

Countries

United States

Trials that died the same way

• Yttrium Y 90 Anti-CD45 Monoclonal Antibody AHN-12 in Treating Patients With Advanced Leukemia
  “Replaced with another study” (98% match in meaning)
• Impact of Neutrophil Extracellular Traps on Tissue Plasminogen Activator Induced Thrombolysis in Acute Ischemic Stroke Patients
  “replaced by a new study” (95% match in meaning)
• Estimate Serum Oxytocin PD Range in the Periphery
  “Study will be replaced by a revised study protocol” (78% match in meaning)
• Use of Magnetic Imaging to Asses the Efficacy of Cap Assisted Colonoscopy in Reducing Looping and Improving Patient Acceptance for the Colonoscopy Procedure
  “The study was incorporated in another study.” (75% match in meaning)
• Effect of Testosterone Gel Replacement on Fat Mass in Males With Low Testosterone Levels and Diabetes
  “study merged with another study” (73% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.